Application and R&D focus
We apply chemistry and peptide R&D across several therapeutic and tool-compound contexts. This is a map of where we are most often engaged—it is not a claim that we treat patients or that any outcome is guaranteed. Every program is different; scoping always starts with your biology, IP, and timeline.
Oncology and immuno-oncology
Small-molecule and peptide programs where selectivity, combination logic, and resistance mechanisms matter in lead design.
- Kinase, E3 ligase, and immune-modulating targets in hit-to-lead and lead optimization.
- Coordination with biology on PD markers, combination windows, and translational readouts as chemistry closes in on a candidate.
Metabolic, endocrine, and inflammation
Ligands and peptides where exposure, organ specificity, and chronic-dosing developability are design drivers.
- GPCRs, nuclear receptors, and enzyme targets with emphasis on ADME, safety, and long-term developability.
CNS and neurology (when exposure allows)
Chemistry and peptide design with brain exposure, efflux, and CNS safety margins in view.
- We align series strategy with your BBB strategy—whether that is small molecules, constrained peptides, or prodrug ideas—without overpromising early PK.
Rare disease and high-unmet-need
Accelerated timelines and material efficiency when every batch counts.
- Tight scoping, route choices that respect limited API, and analytical packages that support first-in-human and natural-history comparisons where applicable.
Anti-infective and resistance-aware design
Selectivity against host targets, resistance pathway awareness, and route feasibility for short-course regimens.
- SAR that tracks resistance mutants and off-target risk in parallel, especially for enzyme and polymerase targets.
Chemical biology, probes, and tool compounds
Rigorous chemistry for mechanistic and target-validation work, not just potency on a single assay.
- Selective modifiers, photopharmacology or covalent tools where appropriate, and clear analytical identity for complex labels or warheads.
Cardiovascular, fibrosis, and renal R&D
Programs where hemodynamics, organ perfusion, and long-term organ safety shape chemistry and peptide choices.
- SAR and developability in tension with off-target CV risk, blood pressure, and organ-selectivity hypotheses.
For service lines and technical depth, see R&D offerings. To discuss your program, contact us.